Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

The Davis Polk corporate team included partner Emily Roberts and associates Jonathan Bye and Paula Gergen. Partner David R. Bauer and associate Mikaela Dealissia provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post